Paris Abstracts angiography (DSA) when used to diagnose peripheral arterial occlusive disease (PAOD) from a German Hospital's perspective. METHODS: In this study we considered the direct cost attributable to the radiological department in a hospital, including proportionate investigation costs such as personnel and machine usage. The costs for contrast agents and consumer goods were considered in a second step as they vary strongly from hospital to hospital. A total of eleven examinations, each of MRA and DSA type, were documented and analyzed. RESULTS: The investigation costs for a MRA examination excluding consumer goods was found to be a142.38 and about 20% (a34.25) lower than that of a DSA-examination (a176.63), owing to the shorter occupation time of the operating room with MRA (average: 32 minutes) than with DSA (average: 58 minutes) and resulting in a lower proportional investigation costs for machine, room, and personnel per examination assuming routine operating hours of 12 hours per day at seven days a week. When the list prices for consumer goods were also regarded, there was still an advantage for MRA of a11.22 ( 7%) per examination. CONCLUSIONS: For patients with suspected PAOD angiography with contrast-enhanced MRA was found to be less costly than DSA. Our results align with cost-effectiveness analyses conducted in the UK and the USA that included in addition the outcomes of diagnosis-based therapeutic decisions. Increased use of contrastenhanced MRA for diagnostic purposes and optimization of cost drivers might promote cost reductions in radiological departments in German hospitals.
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Badalona Serveis Assistencials SA, Barcelona, Spain, 2 Hospital Germans Trias y Pujol, Badalona, Barcelona, Spain, 3 Pfizer Spain, Madrid, Spain OBJECTIVES: To determine the health care cost and the labour incapacity of hypertension (AHT) according to different levels of morbidity in primary care setting (PC) . METHODS: Retrospective-multicentric design. Patients' 40 year from seven 40 year from seven teams of PC (year 2008) were included. Main measures: age, sex, cardiovascular comorbidity, Charlson index and general morbidity levels (Adjusted Clinical Groups; low, moderate and high). It was established a model of direct costs (differentiating: fixed and variable [drugs, tests and referrals]) and indirect. Logistic regression analysis and ANCOVA was used for the model correction. Statistical significance: P 0.05 0.05 RESULTS: The prevalence of hypertension was 28.4% (95% confidence interval [CI]: 27.4-29.4%), mean age 67.5 (11.7) years and 56.7% of female. 73.2% of patients had moderate co-morbidity (95% CI: 71.3-75.1%). The average/unit of the total cost was a1312.1 (range, low co-morbidity: a633.1, moderately: a1297.2 and high: a2307.8, P 0.001). Health care cost represented 98.2% of the whole and medication 0.001). Health care cost represented 98.2% of the whole and medication 69.4%. Morbidity with high cardiovascular event (OR 3.5), smoking (OR 1.4) and obesity (OR 1.3), P 0.02 was associated. The correlation of the health cost and total cost with the episodes number was 51.4% and 50.6% respectively, P 0.001. CONCLUSIONS: Patients with AHT have a high health care cost, mainly in pharmacy. The total costs increase with age and level of general morbidity. The AHT should be considered in conjunction with other cardiovascular risk factors. The cost in work labour incapacity is low.
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COST OF CORONARY ARTERY BYPASS GRAFT (CABG) IN ACUTE HEART FAILURE PATIENTS IN THE CZECH REPUBLIC
Ondrackova B 1 , Miklik R 2 , Parenica J 2 , Spinar J 2 , Sulcova A 1 , Tomcikova D 1 1 Masaryk University, Brno, Czech Republic, 2 University Hospital Brno, Brno, Czech Republic OBJECTIVES: To assess direct in-hospital costs of CABG in patients hospitalized with acute heart failure (AHF) from health care payer perspective and to analyze the burden of CABG procedure in total in-hospital cost of AHF. METHODS: From total 1357 patients hospitalized with AHF in University Hospital Brno (UH) between 2005 and 2007, 4.6% patients were sent to undergo CABG procedure at the Cardio-surgical Centre. Direct cost (include flat rate of admission, stay, medication and service) associated with contiguous AHF hospitalisation and cost of consecutive CABG were evaluated together as well as separately. (1a 28.63CZK). RESULTS: Forty-six patients patients with de-novo AHF and 17 patients with acute decompensation of chronic heart failure were analysed (79.4% male; mean age 68.3 years; 38.7% after myocardial infarction). The median length-of-stay (LOS) in both centres was 25 days, mean cost a11953. Both LOS (median 23.5; 23.5 and 31 days) and costs (mean a 8855; a10,915; a16,742) increased over the years 2005-2007 (statistical significant difference in in-hospital costs p 0.006, Kruskal-Wallis test). 5 patients stayed in intensive care unit (ICU) with median LOS 20 days and mean cost a25,928, others spent median 10 days in ICU and 16 days in standard cardiology unit with mean cost a10748. Stay in UH Brno formed 9.2% total costs (median LOS 11 days; mean a1,098; PCI performed in 7.9% patients); the remainder was concerned with CABG procedure (mean a10,855; LOS 15 days). Two patients (3.2%) died after CABG. CONCLUSIONS: Acute heart failure is a life threatening disease which includes variable causes and complications. One of the most costly procedures in AHF patients is revascularisation by means of percutaneous coronary intervention or CABG. CABG made 15.3% of total in-hospital costs although it was carried out in less than 5% patients.
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EVALUATION OF THE ASSOCIATION BETWEEN SERUM SODIUM AND LENGTH OF STAY (LOS) IN PATIENTS HOSPITALIZED FOR HEART FAILURE
Cyr PL 1 , Slawsky K 1 , Olchanski N 1 , Krasa H 2 , Zimmer C 2 , Ouyang J 2 , Goss TF 3 , Udelson J 4 , Hauptman PL 5 1 Boston Healthcare Associates, Inc., Boston, MA, USA, 2 Otsuka Pharmaceutical Development & Commercialization, Inc., Rockville, MD, USA, 3 Boston Healthcare Associates, Inc., Washington, DC, USA, 4 Tufts Medical Center, Boston, MA, USA, 5 Saint Louis University School of Medicine, Saint Louis, MO, USA OBJECTIVES: Hyponatremia has been associated with risks of in-hospital complications and mortality in patients with heart failure (HF). However, the nature of the relationship between serum sodium (Na) and length of stay in the setting of contemporary HF treatment strategies is not known. We evaluated the impact of hyponatremia on LOS from the multinational EVEREST (Efficacy of Vasopressin Antagonism Efficacy of Vasopressin Antagonism in Heart Failure: Outcome Study with Tolvaptan) trial in patients hospitalized with HF. METHODS: In the standard of care (SOC) arm of EVEREST, initial LOS of normonatremic patients ( 135 mEq/L) was compared to hyponatremic patients ( 135 mEq/L, 130 mEq/L, respectively) to assess the association between Na and overall LOS. Bivariate analysis was performed producing unadjusted mean LOS differences between normatremic and hyponatremic patient cohorts. An analysis of covariance (ANCOVA) model was employed to account for potential regional variation in care delivery. The model was adjusted for hyponatremia status as a factor and both region and hyponatremia status and region interaction as covariates. Significance was assessed with student's t-test at (p 0.05). RESULTS: Patients with admission Na 135 mEq/L (N 216) had an adjusted LOS 3.06 (SE .533) days longer than patients Na 135 mEq/L (N 135 mEq/L (N 1798)(p 0.001). More severely hyponatremic patients ( 130 mEq/L)(N 48) had an adjusted LOS 4.91 (SE 1.16) days longer than those with an admission Na 135 mEq/L (N 135 mEq/L (N 1957)(p 0.001). The magnitude and direction of the association between hyponatremia and LOS was consistent in both the bivariate and multivariate analyses. These findings were also confirmed in the limited subset of U.S. patients: hyponatremia (n 68)( 135 mEq/L) was associated with a LOS 1.39 days longer than normonatremia (n 489)( 135 mEq/L) (p 0.05). CONCLUSIONS: Hyponatremia in patients hospitalized for heart failure is associated with a statistically significant longer LOS as compared with normonatremic patients. Further evaluation of the economic burden of this comorbidity is warranted.
PCV126 REDUCTION IN REHOSPITALIZATIONS AND ASSOCIATED COSTS WITHIN 30 DAYS AFTER DISCHARGE FROM HOSPITALIZATION FOR ACUTE CORONARY SYNDROMES AND PLANNED PCI WITH PRASUGREL VS. CLOPIDOGREL: RESULTS FROM THE TRITON-TIMI 38 TRIAL FOR PATIENTS WITH NO HISTORY OF STROKE OR TIA
Mahoney EM 1 , Wang K 1 , Bae JP 2 , Zhu B 2 , Marciniak MD 2 , Effron MB 2 , Cohen DJ 1 1 Saint Luke's Mid America Heart Institute, Kansas City, MO, USA, 2 Eli Lilly and Company, Indianapolis, IN, USA OBJECTIVES: Readmission within 30 days of discharge following an acute myocardial infarction (AMI) has been adopted as a quality indicator for US hospitals. Whether specific therapeutic interventions lead to reductions in readmissions is unknown. METHODS: We compared rates of readmission within 30 days, and associated hospitalization costs in patients who were originally admitted for acute coronary syndromes (ACS) with planned PCI, and treated with prasugrel vs. clopidogrel in the TRITON-TIMI 38 Trial. Patients with a history of stroke/TIA were excluded. Data for rehospitalizations were collected for patients from 8 pre-specified countries (U.S.,Australia,Canada,Germany,Italy,Spain,UK,France; n 3233 prasugrel, n 3215 clopidogrel). Diagnosis Related Groups (DRGs) were used to classify type of hospitalization, to which average 2005 Medicare reimbursement rates were applied. Rehospitalization rates were compared between groups using Poisson regression. RESULTS: There was a reduction in the 30-day rate of rehospitalization for revascularization (PCI or CABG) with prasugrel vs. clopidogrel (4.33 vs. 5.69 per 100 patients, p 0.015) as well as for PCI (3.80 vs. 4.95 per 100 patients, p 0.03). The reduction in PCI rehospitalizations was primarily among patients with both PCI and AMI (0.31 vs. 1.06, p 0.0006). For patients with an index ST-elevation MI, there was a significant reduction in PCI rehospitalizations in the setting of an MI (0.28 vs. 1.46, p 0.034). The overall 30-day rehospitalization rate did not differ significantly (9.6 prasugrel vs. 10.8 clopidogrel, per 100 patients, p 0.14) though total 30-day rehospitalization costs were lower for prasugrel ($1145 vs. $1419; difference $274, 95% CI: $525, $28). The difference in costs due to PCI-related rehospitalizations was $214 ( $387, 49) . CONCLUSIONS: For ACS patients with no history of stroke/TIA and planned PCI, treatment with prasugrel vs. clopidogrel is associated with a lower rate of rehospitalization for revascularization-primarily PCI in the setting of MI, and concomitant cost savings. These results may be useful in establishing patient management strategies in the current quality and reimbursement environment.
